The FDA has approved valbenazine, also known as INGREZZA, as a treatment for the movement symptoms of Huntington’s disease
In a much-needed bit of good news for the Huntington's disease community, Neurocrine Bioscience's KINECT-HD trial showed that treatment with valbenazine significantly reduced the involuntary movements called chorea
We know that HD-related changes can occur many years before symptom onset, but how early do those changes begin? A team of researchers set out to determine that with a new comprehensive study in pre-manifest HD young adults.
Deutetrabenazine becomes the first new drug in a decade licensed by the FDA for symptoms of Huntington's disease
HDBuzz helps untangle some bold claims about the just-announced results of the PRIDE-HD trial of pridopidine in HD
A new scientific paper & lots of headlines about deutetrabenazine, a twist on treating chorea in Huntington's disease
A genetic study confirms that minute differences in DNA repair genes can influence the age of HD symptom onset.
HD reaches more brain structures than we thought: new research broadens our understanding of the earliest signs of HD
Sleep deficits precede motor problems in HD